Metasztatikus ER+ HER2- férfi emlorák fulvestant és CKD 4/6 inhibitor palbociclib kezelésae többszörös megelozo kemoterápia, endokrin terápia és molekuláris célzott terápia után

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2014-004226-18-HU

Enrollment

Registered

2014-10-02

Start date

2014-10-27

Completion date

Unknown

Last updated

2025-01-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

MedDRA version: 17.0 Level: LLT Classification code 10006191 Term: Breast cancer male NOS System Organ Class: 100000004864

Interventions

Product Name: Palbociclib Pharmaceutical Form: Capsule Other descriptive name: PALBOCICLIB Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 125-

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 1 F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Main Objective: ;Secondary Objective: ;Primary end point(s):	—

Countries

Hungary

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026